Whistler Conference Centre Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2019
Here are the related meetings in 2020:
Advances in Cancer Immunotherapy (C4)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (C2)
Organizer(s) Padmanee Sharma, Aviv Regev, Crystal L. Mackall and Kristen Hege
March 10—14, 2019
Whistler Conference Centre • Whistler, British Columbia Canada
Discounted Abstract Deadline: Nov 20, 2018
Abstract Deadline: Dec 5, 2018
Scholarship Deadline: Nov 20, 2018
Discounted Registration Deadline: Jan 15, 2019
Sponsored by Autolus Therapeutics, Bayer AG, BioLegend, Inc., Bristol-Myers Squibb Company, Cell Research, ImmunoGen, Inc., Incyte Corporation, MedImmune, Merck & Co., Inc., Roche, Surface Oncology, TESARO, Inc., Takeda Pharmaceutical Company Limited and Tessa Therapeutics Ltd.
Summary of Meeting:
Cancer immunotherapy is an established field that has led to remarkable clinical benefit for a subset of patients. However, a deeper understanding of the mechanisms of response and resistance to current immunotherapy strategies is needed to help develop new treatments that will increase the number of patients who will benefit. This Keystone Symposia conference is focused on immunotherapy as a treatment for cancer, including potential combination therapies and development of new technologies to elucidate novel targets and/or biomarkers that will be used to design new treatments and enable appropriate patient selection to improve clinical outcomes for cancer patients. The conference will bring together leading and emerging scientists to advance the development of new immune-based treatments for cancer. Discussions will also consider the future directions of the field, including the identification of the most pressing unanswered questions, the areas needing more focus, and those that would benefit from new approaches and methodologies developed and used in other related fields.
View Scholarships/Awards
Cancer immunotherapy is an established field that has led to remarkable clinical benefit for a subset of patients. However, a deeper understanding of the mechanisms of response and resistance to current immunotherapy strategies is needed to help develop new treatments that will increase the number of patients who will benefit. This Keystone Symposia conference is focused on immunotherapy as a treatment for cancer, including potential combination therapies and development of new technologies to elucidate novel targets and/or biomarkers that will be used to design new treatments and enable appropriate patient selection to improve clinical outcomes for cancer patients. The conference will bring together leading and emerging scientists to advance the development of new immune-based treatments for cancer. Discussions will also consider the future directions of the field, including the identification of the most pressing unanswered questions, the areas needing more focus, and those that would benefit from new approaches and methodologies developed and used in other related fields.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, March 10 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 14 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 15 in order to fully experience the meeting.
SUNDAY, MARCH 10
MONDAY, MARCH 11
TUESDAY, MARCH 12
WEDNESDAY, MARCH 13
THURSDAY, MARCH 14
FRIDAY, MARCH 15
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, March 10 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 14 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 15 in order to fully experience the meeting.
SUNDAY, MARCH 10
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.
*
Padmanee Sharma,
University of Texas MD Anderson Cancer Center, USA
Catherine Ju-Ying Wu,
Dana-Farber Cancer Institute, USA
Identifying and Targeting Tumor Neoantigens
Identifying and Targeting Tumor Neoantigens
09:00—11:30
Response and Resistance Mechanisms to Cancer Immunotherapy
Meeting has ended...abstracts no longer viewable online.
*
Padmanee Sharma,
University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy
From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy
Coffee Break
Philip D. Greenberg,
University of Washington, USA
Resistance Mechanisms to Engineered T Cell Therapies
Resistance Mechanisms to Engineered T Cell Therapies
*
Robert D. Schreiber,
Washington University School of Medicine, USA
The Molecular Cell Biology of Immune Control and Escape of Cancer
The Molecular Cell Biology of Immune Control and Escape of Cancer
Yuliya Pylayeva-Gupta,
University of North Carolina at Chapel Hill, USA
Short Talk: IL-35+ B Cells Establish Immunosuppressive Network in Pancreatic Ductal Adenocarcinoma
Short Talk: IL-35+ B Cells Establish Immunosuppressive Network in Pancreatic Ductal Adenocarcinoma
Robert T. Manguso,
Dana-Farber Cancer Institute/Harvard Medical School, USA
Short Talk: Loss of ADAR1 in Tumors Overcomes Resistance to Immune Checkpoint Blockade
Short Talk: Loss of ADAR1 in Tumors Overcomes Resistance to Immune Checkpoint Blockade
14:30—16:30
Workshop 1: Engaging New Mechanisms to Improve Cancer Immunotherapy
Donald E. Staunton,
Arbele Corporation, USA
Bispecific CDH17/CD3 Antibodies with High Tumor Specificity, Cytotoxicity and Safety in Non-Human Primates
Bispecific CDH17/CD3 Antibodies with High Tumor Specificity, Cytotoxicity and Safety in Non-Human Primates
Krzysztof Masternak,
NovImmune SA, Switzerland
CD47-Blocking Bispecific Antibodies Increase in vivo Phagocytosis of Tumor Cells and Modify the Tumor Microenvironment
CD47-Blocking Bispecific Antibodies Increase in vivo Phagocytosis of Tumor Cells and Modify the Tumor Microenvironment
Limei Shen,
University of North Carolina, USA
Nano-trapping B Cell Chemoattractant CXCL13 Reduces Bregs in Tumor Microenvironment and Inhibits Desmoplastic Tumors in Murine Orthotopic Models
Nano-trapping B Cell Chemoattractant CXCL13 Reduces Bregs in Tumor Microenvironment and Inhibits Desmoplastic Tumors in Murine Orthotopic Models
Adrienne H. Long,
Dana-Farber Cancer Institute, USA
Inhibition of Signal Peptide Peptidase Triggers Novel Antigen Presentation on Non-Classical MHC and Sensitizes Tumors to Checkpoint Blockade
Inhibition of Signal Peptide Peptidase Triggers Novel Antigen Presentation on Non-Classical MHC and Sensitizes Tumors to Checkpoint Blockade
*
Shruthy Suresh,
University of Texas Southwestern Medical Center, USA
The Integrated Stress Response Pathway Controls PD-L1 Translation in Lung Cancer
The Integrated Stress Response Pathway Controls PD-L1 Translation in Lung Cancer
Andrew G. Thomason,
Redx Pharma, UK
Wnt Pathway Suppression with Porcupine Inhibitor RXC004 Enhances the Immune Response against Tumours
Wnt Pathway Suppression with Porcupine Inhibitor RXC004 Enhances the Immune Response against Tumours
*
Patrick A. Ott,
Dana-Farber Cancer Institute, USA
Complex Inter-Relationship of Body Mass Index, Gender and Serum Creatinine on Survival: Exploring the Obesity Paradox in Melanoma Patients Treated with Immune Checkpoint Inhibition
Complex Inter-Relationship of Body Mass Index, Gender and Serum Creatinine on Survival: Exploring the Obesity Paradox in Melanoma Patients Treated with Immune Checkpoint Inhibition
17:00—19:00
Technological Advances for Dissecting Immune Responses
Meeting has ended...abstracts no longer viewable online.
*
Elaine R. Mardis,
Nationwide Children's Hospital, USA
Genomic Exploration of the Pediatric CNS Tumor Microenvironment
Genomic Exploration of the Pediatric CNS Tumor Microenvironment
James P. Allison,
University of Texas MD Anderson Cancer Center, USA
Immune Checkpoint Therapy: Lessons Learned and Next Steps
Immune Checkpoint Therapy: Lessons Learned and Next Steps
Jonathan Fisher,
University College London, UK
Short Talk: Mass Cytometric Analysis of CAR Signaling – Single Cell Engine Diagnostics Reveals Problems and Solutions
Short Talk: Mass Cytometric Analysis of CAR Signaling – Single Cell Engine Diagnostics Reveals Problems and Solutions
Martin LaFleur,
Harvard Medical School, USA
Short Talk: CHIME: A Chimeric CRISPR-Cas9 Delivery System for Pooled in vivo Screening of Genes in the Immune System
Short Talk: CHIME: A Chimeric CRISPR-Cas9 Delivery System for Pooled in vivo Screening of Genes in the Immune System
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Improving Anti-Tumor Immune Responses
Meeting has ended...abstracts no longer viewable online.
*
Aviv Regev,
Massachusetts Institute of Technology, USA
Comprehending Anti-Tumor Immune Responses through Single-Cell Studies
Comprehending Anti-Tumor Immune Responses through Single-Cell Studies
Coffee Break
Thomas Gajewski,
University of Chicago, USA
Identifying Mechanisms to Facilitate a T Cell-Inflamed Tumor Microenvironment
Identifying Mechanisms to Facilitate a T Cell-Inflamed Tumor Microenvironment
*
Niroshana Anandasabapathy,
Weill Cornell Medicine, USA
Targeting T Cell:DC Cross Talk in the Periphery to Expand Anti-Tumor Immunity
Targeting T Cell:DC Cross Talk in the Periphery to Expand Anti-Tumor Immunity
Shannon K. Oda,
Fred Hutchinson Cancer Research Center, USA
Short Talk: A Fas-4-1BB Immunomodulatory Fusion Protein Enhances Function and Metabolism of Engineered T cells and Improves Immunotherapy of Liquid and Solid Tumors
Short Talk: A Fas-4-1BB Immunomodulatory Fusion Protein Enhances Function and Metabolism of Engineered T cells and Improves Immunotherapy of Liquid and Solid Tumors
14:30—16:30
Workshop 2: Engineered T Cells
Mauro Castellarin,
University of Pennsylvania, USA
A Universal Chimeric Antigen Receptor System for Switching Target Recognition by CAR T Cells
A Universal Chimeric Antigen Receptor System for Switching Target Recognition by CAR T Cells
Philip S. Low,
Purdue University, USA
Evaluation of a Universal CAR T Cell Technology in Murine Tumor Models
Evaluation of a Universal CAR T Cell Technology in Murine Tumor Models
Louai Labanieh,
Stanford University, USA
Controlling CAR-T Function with an FDA-Approved Small Molecule
Controlling CAR-T Function with an FDA-Approved Small Molecule
Henri Bayle,
Bellicum Pharmaceuticals, USA
Control of CAR-Natural Killer Cell Expansion and Anti-Tumor Activity with Inducible MyD88/CD40 and Small Molecules
Control of CAR-Natural Killer Cell Expansion and Anti-Tumor Activity with Inducible MyD88/CD40 and Small Molecules
Tori Yamamoto,
NCI, University of Pennsylvania, USA
T Cells Engineered to Overcome Death Signaling within the Tumor Microenvironment Enhance Adoptive Cancer Immunotherapy
T Cells Engineered to Overcome Death Signaling within the Tumor Microenvironment Enhance Adoptive Cancer Immunotherapy
Robert Josef Hofmeister,
TCR2 Therapeutics, USA
Preclinical Evaluation of TC-210, a Mesothelin-Specific T Cell Receptor (TCR) Fusion Construct (TRuC™) T Cells for the Treatment of Solid Tumors
Preclinical Evaluation of TC-210, a Mesothelin-Specific T Cell Receptor (TCR) Fusion Construct (TRuC™) T Cells for the Treatment of Solid Tumors
*
Beatrice Greco,
Vita-Salute San Raffaele University, Italy
Combining De-Glycosylating Agents with CAR-T Cells for Targeting Solid Tumors and Reducing Toxicity
Combining De-Glycosylating Agents with CAR-T Cells for Targeting Solid Tumors and Reducing Toxicity
*
Melody Smith,
Memorial Sloan Kettering Cancer Center, USA
Intestinal Microbiome Analyses Identify Biomarkers for Patient Response to CAR T Cell Therapy
Intestinal Microbiome Analyses Identify Biomarkers for Patient Response to CAR T Cell Therapy
17:00—19:00
Engineering T Cells
Meeting has ended...abstracts no longer viewable online.
*
Crystal L. Mackall,
Stanford University, USA
Engineering Exhaustion Resistant T Cells to Enhance the Efficacy of CAR-Based Therapies
Engineering Exhaustion Resistant T Cells to Enhance the Efficacy of CAR-Based Therapies
*
Kristen Hege,
Celgene, USA
Clinical Development of BCMA CAR T Cells in Myeloma
Clinical Development of BCMA CAR T Cells in Myeloma
Megan Dacek,
Memorial Sloan Kettering Cancer Center, USA
Short Talk: Potentiating Innate and Adaptive Immunity with Engineered CAR T Cells
Short Talk: Potentiating Innate and Adaptive Immunity with Engineered CAR T Cells
Evan William Weber,
Stanford University, USA
Short Talk: Transient Rest Reverses CAR T Cell Exhaustion and Augments Efficacy
Short Talk: Transient Rest Reverses CAR T Cell Exhaustion and Augments Efficacy
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Immune Checkpoints: Basic Mechanisms and Novel Targets
Meeting has ended...abstracts no longer viewable online.
Chris H. Takimoto,
Forty Seven, Inc., USA
Enhancing Antitumor Immunity by Inhibiting CD47 Signaling: An Overview of CD47 Targeting Agents in Clinical Development
Enhancing Antitumor Immunity by Inhibiting CD47 Signaling: An Overview of CD47 Targeting Agents in Clinical Development
*
Sangeeta Goswami,
MD Anderson Cancer Center, USA
Modulation of Immune Checkpoint Therapy Responses by Immune Cell Inherent Epigenetic Machinery
Modulation of Immune Checkpoint Therapy Responses by Immune Cell Inherent Epigenetic Machinery
Coffee Break
Willem W. Overwijk,
Nektar Therapeutics, USA
Intratumoral Expansion of CD8+ T cells and Depletion of Tregs after Treatment with NKTR-214, a First-In-Class, CD122-Preferential IL-2 Pathway Agonist
Intratumoral Expansion of CD8+ T cells and Depletion of Tregs after Treatment with NKTR-214, a First-In-Class, CD122-Preferential IL-2 Pathway Agonist
*
Xiaoyan Michelle Zhang,
Kyn Therapeutics, USA
Kynureninase and AHR Inhibition, Novel and Differentiated Approaches Targeting IDO1/TDO2/Kynurenine Pathway and Beyond
Kynureninase and AHR Inhibition, Novel and Differentiated Approaches Targeting IDO1/TDO2/Kynurenine Pathway and Beyond
Martina Seiffert,
German Cancer Research Center, Germany
Short Talk: IL-10/STAT3 Signaling Overcomes Tumor-Induced Exhaustion of CD8+ T-Cells
Short Talk: IL-10/STAT3 Signaling Overcomes Tumor-Induced Exhaustion of CD8+ T-Cells
Dana Emerson,
Oregon Health and Science University, USA
Short Talk: ITK Inhibition Augments the Therapeutic Efficacy of anti-OX40/anti-CTLA-4 Immunotherapy via Enhanced Eomes Expression and Effector T-Cell Responses
Short Talk: ITK Inhibition Augments the Therapeutic Efficacy of anti-OX40/anti-CTLA-4 Immunotherapy via Enhanced Eomes Expression and Effector T-Cell Responses
Tao Dong,
University of Oxford, UK
Short Talk: A Comprehensive Analysis of Key Immune Checkpoint Receptors on T Cells Indicates Mono-or Combinatorial Blockade Immunotherapy in Multiple Types of Cancer
Short Talk: A Comprehensive Analysis of Key Immune Checkpoint Receptors on T Cells Indicates Mono-or Combinatorial Blockade Immunotherapy in Multiple Types of Cancer
17:00—19:00
Combinatorial Immunotherapy Strategies
Meeting has ended...abstracts no longer viewable online.
*
Sandra Demaria,
Weill Cornell Medical College, USA
Using Precision Radiotherapy to Ignite Anti-Tumor Immunity with Immunotherapy
Using Precision Radiotherapy to Ignite Anti-Tumor Immunity with Immunotherapy
Juan C. Jaen,
Arcus Biosciences, Inc., USA
Targeting Immune Activation via Inhibition of the Adenosine Pathway
Targeting Immune Activation via Inhibition of the Adenosine Pathway
*
Antoni Ribas,
University of California, Los Angeles, USA
Novel Combination Therapy Strategies
Novel Combination Therapy Strategies
Peter Goff,
University of Washington, USA
Short Talk: Newcastle Disease Virus Works Synergistically with Radiotherapy to Enhance Checkpoint Blockade and Improve Long-Term Survival in a Murine Melanoma Model
Short Talk: Newcastle Disease Virus Works Synergistically with Radiotherapy to Enhance Checkpoint Blockade and Improve Long-Term Survival in a Murine Melanoma Model
Sarah L. Buchan,
University of Southampton, UK
Short Talk: PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs that Synergize for CD8+ T-Cell Driven Anti-Tumor Immunity
Short Talk: PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs that Synergize for CD8+ T-Cell Driven Anti-Tumor Immunity
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Progress Report on Immune Monitoring and Clinical Trials
Meeting has ended...abstracts no longer viewable online.
Robert H. Vonderheide,
University of Pennsylvania, USA
Immunogenic Properties of Mutant KRAS
Immunogenic Properties of Mutant KRAS
Ton N. Schumacher,
Netherlands Cancer Institute, Netherlands
Regulation of Immune Recognition by the CD47 and PD-L1 Immune Checkpoints
Regulation of Immune Recognition by the CD47 and PD-L1 Immune Checkpoints
Coffee Break
*
Sumit Kumar Subudhi,
MD Anderson Cancer Center, USA
Immune Checkpoint Therapies in Prostate Cancer
Immune Checkpoint Therapies in Prostate Cancer
*
Cornelia Liu Trimble,
Johns Hopkins University School of Medicine, USA
Therapeutic Vaccination for Intraepithelial Disease: Lessons Learned from HPV
Therapeutic Vaccination for Intraepithelial Disease: Lessons Learned from HPV
Hideho Okada,
University of California, San Francisco, USA
Short Talk: Targeting H3.3 K27M Mutation as a Shared Neoantigen in HLA-A*0201+ Patients with Diffuse Midline Gliomas – Development of a Novel Mass Cytometry-Based Monitoring of Vaccine-Reactive, Epitope-Specific CD8+ T Cell Responses
Short Talk: Targeting H3.3 K27M Mutation as a Shared Neoantigen in HLA-A*0201+ Patients with Diffuse Midline Gliomas – Development of a Novel Mass Cytometry-Based Monitoring of Vaccine-Reactive, Epitope-Specific CD8+ T Cell Responses
Akil A. Merchant,
Cedars-Sinai Medical Center, USA
Short Talk: Highly Multiplexed Imaging Mass Cytometry Reveals Immune Cell Composition and Spatial Heterogeneity in Diffuse Large B Cell Lymphoma Associated with Treatment Outcome
Short Talk: Highly Multiplexed Imaging Mass Cytometry Reveals Immune Cell Composition and Spatial Heterogeneity in Diffuse Large B Cell Lymphoma Associated with Treatment Outcome
Colleen Annesley,
Seattle Children's Hospital, USA
Short Talk: Novel CD19t T-Antigen-Presenting Cells Expand CD19 CAR T Cells in vivo
Short Talk: Novel CD19t T-Antigen-Presenting Cells Expand CD19 CAR T Cells in vivo
14:30—16:30
Workshop 3: Engineering Novel Therapeutic Agents
Michael Schebesta,
Obsidian Therapeutics, USA
Enhancing Adoptive Cell Therapies Through Regulation of CD40L
Enhancing Adoptive Cell Therapies Through Regulation of CD40L
*
Nadia Coltella,
Universita' Vita-Salute San Raffaele, Italy
Development of Chimeric Forms of IFN-α for Inducible in vivo Cancer Gene Therapy
Development of Chimeric Forms of IFN-α for Inducible in vivo Cancer Gene Therapy
Sriram Sathyanarayanan,
Codiak BioSciences, USA
Developing an Engineered Exosome Therapeutic Platform for Immuno-Oncology
Developing an Engineered Exosome Therapeutic Platform for Immuno-Oncology
Chris Saxby,
University of Washington, USA
Engineered Cytokine Receptors Support CAR T Cell Mediated Tumor Removal
Engineered Cytokine Receptors Support CAR T Cell Mediated Tumor Removal
*
Sara Schad,
Memorial Sloan Kettering Cancer Center, USA
Phosphatidylserine Targeting Antibody Enhances Anti-Tumor Activity of CAR T Cell Therapy in a Mouse Melanoma Model
Phosphatidylserine Targeting Antibody Enhances Anti-Tumor Activity of CAR T Cell Therapy in a Mouse Melanoma Model
Scott T. Walsh,
NCI, National Institutes of Health, USA
Development of a Novel Interleukin-7 Hydrogel Delivery System for T cell Applications
Development of a Novel Interleukin-7 Hydrogel Delivery System for T cell Applications
17:00—18:45
The Future of Cancer Immunotherapy
Meeting has ended...abstracts no longer viewable online.
*
Jennifer Ann Wargo,
University of Texas MD Anderson Cancer Center, USA
Microbiome Targeting and Future Strategies to Improve Cancer Immunotherapy
Microbiome Targeting and Future Strategies to Improve Cancer Immunotherapy
*
Michael C. Jensen,
Seattle Children's Research Institute, USA
Regulating the Next Generation of Genetically Enhanced CAR T Cells
Regulating the Next Generation of Genetically Enhanced CAR T Cells
Flavius Martin,
Amgen, Inc., USA
Learnings from Bispecific T-Cell Engagers, from Bedside Back to the Bench
Learnings from Bispecific T-Cell Engagers, from Bedside Back to the Bench
Darren Austin Plumb,
PsiOxus Therapeutics, UK
Short Talk: Development of an Oncolytic T-SIGn Virus, NG-641, Targeting Cancer-Associated Fibroblasts for the Treatment of Stroma-Rich Carcinomas
Short Talk: Development of an Oncolytic T-SIGn Virus, NG-641, Targeting Cancer-Associated Fibroblasts for the Treatment of Stroma-Rich Carcinomas
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We gratefully acknowledge additional support from these exhibitors at this conference:
|
|
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
